EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 2a

Ensembl ID : ENSMAMG00000011473
Gene Symbol: ATP1B2A
2 Cross references
200 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSMAMG00000014390
Gene Symbol: ATP1B2B
3 Cross references
203 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSMAMG00000003516
Gene Symbol: ATP1B3A
3 Cross references
236 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3b

Ensembl ID : ENSMAMG00000018111
Gene Symbol: ATP1B3B
2 Cross references
232 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSMAMG00000001677
Gene Symbol: ATR
2 Cross references
205 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSMAMG00000014817
Gene Symbol: AXL
3 Cross references
187 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMAMG00000023278
Gene Symbol: BRAF
3 Cross references
218 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSMAMG00000006160
Gene Symbol: LOC113135822
2 Cross references
167 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSMAMG00000016668
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSMAMG00000020415
Gene Symbol: SI:DKEY-91M11.5
3 Cross references
196 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSMAMG00000007621
Gene Symbol: BCR
2 Cross references
205 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSMAMG00000019718
Gene Symbol: BTK
2 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).